AstraZeneca

Algen Biotechnologies announced a multi-target partnership with AstraZeneca worth up to $555 million to accelerate discovery of novel therapeutic targets in immunology using AI-powered drug discovery.

Amgen's Phase III VESALIUS-CV trial met both primary endpoints, demonstrating that Repatha significantly reduces major adverse cardiovascular events in high-risk patients without prior heart attack or stroke.

Thermo Fisher Scientific's PPD clinical research business has established a new R&D partnership with AstraZeneca BioVentureHub in Gothenburg, Sweden, focusing on collaborative innovation in life sciences.

Irish biotech startup Aerska has secured $21 million in seed funding to develop RNA interference therapies targeting degenerative neurological diseases including Alzheimer's and Parkinson's disease.

Crystalys Therapeutics launched with $205 million in Series A funding to develop dotinurad, a URAT1 blocker for gout treatment that is already approved in Japan, China, Philippines, and Thailand.

Novartis will launch a direct-to-patient platform on November 1, 2025, offering Cosentyx at a 55% discount off list price to cash-paying patients in the US.

A randomized controlled trial of 360 children aged 5-15 found that a budesonide-formoterol combination inhaler reduced asthma attacks by 45% compared to standard salbutamol treatment.

Factor Bioscience filed a patent lawsuit against Cellectis and AstraZeneca in Delaware federal court, alleging infringement of three foundational gene-editing patents related to mRNA TALEN technology.

AstraZeneca announced it will offer its diabetes drug Farxiga and asthma drug Airsupra at discounts of up to 70% through a new direct-to-consumer platform launching October 1, 2025.

AIM ImmunoTech has secured a Japanese patent covering Ampligen (rintatolimod) in combination with checkpoint inhibitors for cancer treatment, valid until December 20, 2039.